| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $15.2M | — | -1.6% |
| SG&A Expense | $4.7M | — | -24.2% |
| Operating Income | -$19.9M | — | +8.1% |
| Net Income | -$19.0M | — | +3.2% |
| EPS (Basic) | -$0.49 | — | +3.9% |
| EPS (Diluted) | -$0.49 | — | +3.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $34.1M | -17.9% | -13.0% |
| Short-term Investments | $63.7M | -17.4% | -42.4% |
| Current Assets | $99.2M | -17.6% | -34.4% |
| Total Assets | $107.8M | -16.9% | -38.9% |
| Current Liabilities | $11.1M | -29.4% | -18.4% |
| Total Liabilities | $12.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$20.5M | — | -5.1% |
| Capital Expenditures | $14K | — | -75.9% |
| Investing Cash Flow | $13.1M | — | -31.7% |
| Financing Cash Flow | -$33K | — | +90.4% |
| Free Cash Flow | -$20.6M | — | -4.9% |
| -22.8% |
| Stockholders' Equity | $95.5M | -15.1% | -40.4% |